Multiple Sclerosis (MS) Support Group

This community is a place where members can discuss current events and weigh in on what's going on in the world.

0 Online

brianap 10/15/2010

I was reading the outcomes of the study and the numbers sounded great. 96% reduction in lesions? 80% reduction in relapse? Then I went to Wikipedia to read about side effects. It stated that the drug was tested in rheumatiod arthritis and lupus as well. However they stopped those trials to to deaths form opportunistic infection. The MS trial was still on going. Hmm. We can't fix 'em. so maybe we'll just kill 'em.

http://www.manufacturing.net/News/Feeds/2010/10/mnet-market-sectors-pharmaceuticals/biotech-phase-ii-study-with-ocrelizumab-shows-significant-/

deleted_user 10/16/2010

I didn't look extensively, but it could be that the reaction in MS patients is different, and it could also be that the dose required for a positive outcome is lower with MS. Or they are trying to kill us!

It did appear that the numbers for skin cancer and herpes were very low, but this is at 24 weeks. I am a little unimpressed with a study of 222 MS patients which is making claims about a reduction in lesions and relapses. The disease is...RR...so despite the comparison of a placebo group to medicated group, well, that would be like you and I, one taking a drug and one not and then seeing which one did and did not relapse...would we have or have not anyway? I just don't put alot of stock in short-term trials that claim to change relapse periods, and especially when they are using MRI results as part of that measure, raise your hand if your relapses are all related to a lesion or if they are something you can chart like clockwork.

Join the Conversation